AMETEK Lags Peers Into Q3 as Call Skew Holds

AME closed Friday at $241.12, down 4.2% on the day and 3.9% over the past month, yet options traders are not treating the pullback as a reason to hedge. The put/call ratio stands at 0.26, virtually flat against its 20-day average of 0.26 and near the 52-week low of 0.23, meaning calls continue to dominate the options market by a wide margin.

The peer divergence is the sharpest data point into Monday's Q3 report. AME gained just 0.5% over the past week while its closest industrial peers moved in the opposite direction: GEV rose 7.3%, ETN 6.7%, EMR 6.5%, and RRX 10.0%. Even NVT, which lagged earlier in the month, gained 8.2%. AME was the only name in the group to underperform meaningfully, a pattern that reflects Thursday's 4.2% drop pulling the weekly figure negative against a peer median above 7%. That single-day move, occurring the day prior to the earnings event listed in October, appears to have reset the stock's entry point without prompting a rush to buy protection.

The borrow market reinforces that shorts have no strong conviction here. Short interest is 1.6% of the free float, a level that carries no meaningful signal on its own, and borrow costs have eased sharply, dropping to 0.35%, down 17% on the week and more than 50% over the past month. Borrow availability is essentially uncapped. That combination leaves the lending market a non-story going into the print.

Analysts are broadly constructive, though the most recent moves show some calibration rather than a directional shift. Citigroup raised its target to $263 in mid-October while holding a Neutral rating, consistent with its posture after August's Q2 results. The wider Street has a consensus target near $282, implying roughly 17% above the current price, with Buy-side firms including TD Cowen, Truist, and DA Davidson all carrying targets in the $275 to $316 range. The debate is less about AMETEK's business quality, record Q1 organic orders of $2.2 billion, backlog near $3.9 billion, margins at 27.9%, and more about whether the current multiple, at roughly 27 times earnings and 19.6 times EV/EBITDA, is justified if the Q3 update shows the high-single-digit sales growth management flagged for Q2 is still the pace of travel.

The Q3 print on November 3 will test whether AMETEK's relative underperformance against peers this past week reflects company-specific caution ahead of results, or simply mechanical catch-up after a month in which the stock had held up better than the group.